zoledronic acid has been researched along with Gout in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aati, O; Chhana, A; Dalbeth, N; Doyle, AJ; Gamble, GD; Horne, A; House, ME; McQueen, FM; Reid, IR; Roger, M | 1 |
| Aati, O; Callon, KE; Chhana, A; Cornish, J; Dalbeth, N; Doyle, AJ; Gamble, GD; Horne, A; McQueen, FM; Reid, IR; Roger, M | 1 |
2 trial(s) available for zoledronic acid and Gout
| Article | Year |
|---|---|
Zoledronate for prevention of bone erosion in tophaceous gout: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Foot Bones; Gout; Humans; Imidazoles; Male; Middle Aged; Spine; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2014 |
Path Analysis Identifies Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Sclerostin as Potential Mediators of the Tophus-bone Erosion Relationship in Gout.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Bone and Bones; Bone Morphogenetic Proteins; Bone Remodeling; Diphosphonates; Female; Genetic Markers; Gout; Humans; Imidazoles; Male; Middle Aged; Osteoprotegerin; RANK Ligand; Zoledronic Acid | 2016 |